Indeed, we have demonstrated that low levels of CCDC6 protein increase lung cancer cells’ sensitivity to the sole olaparib treatment; moreover, olaparib synergizes with cisplatinum in killing cells [34]. This evidence concerns the gene CCDC6 and lung carcinoma.